SVAS (Supravalvular Aortic Stenosis) is a rare condition where the aorta loses elasticity, causing dangerous thickening and narrowing. Using stem-cell technology, the researcher converts skin cells into aortic smooth muscle cells to study the disease and test treatments. A promising compound restores elasticity-related structures, offering hope for future therapies and broader disease modelling.

This research tests the safety of a new hypertension drug designed for patients who don’t respond to current medications. Through four phases of pre-clinical toxicology studies in cells and mice, the drug showed no major toxicity and effectively lowered blood pressure, supporting its progression toward future human clinical trials.